Comparable stake leader
Royalty Pharma Investments 2019 ICAV
SEC ownership of Epizyme, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001571498.
Disclosed value leader
Royalty Pharma Investments 2019 ICAV
Comparable rows
0/4
Latest evidence
12 Aug 2022
- Parsed ownership sources
-
3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Royalty Pharma Investments 2019 ICAV
Ranking: Comparable ownership first, then disclosed value
- Latest parsed ownership date
-
12 Aug 2022
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001571498
- Issuer location
- Cambridge, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Epizyme, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Royalty Pharma Investment...
Disclosed value leader
Royalty Pharma Investment...
Comparable rows
0/4
Latest evidence
12 Aug 2022
3/4/5
Highest disclosed value: $31,960,000
4 rows are not safely comparable across share classes.
Quick read
Royalty Pharma Investments 2019 ICAV has the largest disclosed position value at $31.96M.
0 of 4 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Royalty Pharma Investments 2019 ICAV's linked filing trail.
Disclosed position value
Top 3
Royalty Pharma Investments 2019 ICAV
$31.96M
Matthew Ros
$157K
Andrew R. Allen
$29K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-4 of 4 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Royalty Pharma Investments 2019 ICAV |
3/4/5
Director, 10%+ Owner
|
—
class O/S missing
|
$31,960,000
22,666,667 shares
|
— | 31 Jan 2022 |
| Matthew Ros |
3/4/5
Executive Vice President, Chief Strategy & Business Officer
|
—
mixed-class rows
|
$156,951
245,491 shares
mixed-class rows
|
— | 16 Aug 2021 |
| Andrew R. Allen |
3/4/5
Director
|
—
mixed-class rows
|
$28,990
61,119 shares
mixed-class rows
|
— | 11 Jun 2021 |
| Jerald Korn |
3/4/5
Chief Operating Officer
|
—
class O/S missing
|
—
800,000 shares
|
— | 12 Aug 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 05 Sep 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-17 of 17 reporting-owner rows connected to Epizyme, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
17
Largest Forms 3/4/5 holder
Royalty Pharma Investments 2019 ICAV
Net 12M change
$0
Latest report
12 Aug 2022
Recent insider transactions for Epizyme, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.